SEARCH

SEARCH BY CITATION

References

  • 1
    Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis. J Am Coll Cardiol 2009; 54:21292138.
  • 2
    Carter AM. Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res 2005; 2:113121.
  • 3
    Oksjoki R, Kovanen PT, Meri S et al. Function and regulation of the complement system in cardiovascular diseases. Front Biosci 2007; 12:46964708.
  • 4
    Speidl WS, Kastl SP, Huber K et al. Complement in atherosclerosis: friend or foe? J Thromb Haemost 2011; 9:428440.
  • 5
    Frauenknecht V, Schroeder V. Complement – a phylogenetically old system as a new player in the development of atherosclerosis [in German]. Hämostaseologie 2012; 32:276285.
  • 6
    Banz Y, Rieben R. Role of complement and perspectives for intervention in ischemia-reperfusion damage. Ann Med 2012; 44:205217.
  • 7
    Markiewski MM, Nilsson B, Nilsson Ekdahl K et al. Complement and coagulation: strangers or partners in crime? Trends Immunol 2007; 28:184192.
  • 8
    Amara U, Flierl MA, Rittirsch D et al. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010; 185:56285636.
  • 9
    Ricklin D, Hajishengallis G, Yang K et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785797.
  • 10
    Hansen S, Selman L, Palaniyar N et al. Collectin 11 (CL-11, CL-K1) is a MASP-1/3-associated plasma collectin with microbial-binding activity. J Immunol 2010; 185:60966104.
  • 11
    Yongqing T, Drentin N, Duncan RC et al. Mannose-binding lectin serine proteases and associated proteins of the lectin pathway of complement: two genes, five proteins and many functions? Biochim Biophys Acta 2012; 1824:253262.
  • 12
    Degn SE, Jensenius JC, Thiel S. Disease-causing mutations in genes of the complement system. Am J Hum Genet 2011; 88:689705.
  • 13
    Kidmose RT, Laursen NS, Dobó J et al. Structural basis for activation of the complement system by C4 cleavage. Proc Natl Acad Sci USA 2012; 109:1542515430.
  • 14
    Degn SE, Jensen L, Hansen AG et al. Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function. J Immunol 2012; 189:39573969.
  • 15
    Héja D, Kocsis A, Dobó J et al. Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2. Proc Natl Acad Sci USA 2012; 109:1049810503.
  • 16
    Sirmaci A, Walsh T, Akay H et al. MASP1 mutations in patients with facial, umbilical, coccygeal, and auditory findings of Carnevale, Malpuech, OSA, and Michels syndromes. Am J Hum Genet 2010; 87:679686.
  • 17
    Rooryck C, Diaz-Font A, Osborn DP et al. Mutations in lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome. Nat Genet 2011; 43:197203.
  • 18
    Skjoedt MO, Palarasah Y, Munthe-Fog L et al. MBL-associated serine protease-3 circulates in high serum concentrations predominantly in complex with ficolin-3 and regulates ficolin-3 mediated complement activation. Immunobiology 2010; 215:921931.
  • 19
    Dahl MR, Thiel S, Matsushita M et al. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 2001; 15:127135.
  • 20
    Iwaki D, Kanno K, Takahashi M et al. The role of mannose-binding lectin-associated serine protease-3 in activation of the alternative complement pathway. J Immunol 2011; 187:37513758.
  • 21
    Degn SE, Hansen AG, Steffensen R et al. MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation. J Immunol 2009; 183:73717378.
  • 22
    Skjoedt MO, Roversi P, Hummelshøj T et al. Crystal structure and functional characterization of the complement regulator mannose-binding lectin (MBL)/ficolin-associated protein-1 (MAP-1). J Biol Chem 2012; 287:3291332921.
  • 23
    Pavlov VI, Skjoedt MO, Tan YS et al. Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis. Circulation 2012; 126:22272235.
  • 24
    Hajela K, Kojima M, Ambrus G et al. The biological functions of MBL-associated serine proteases (MASPs). Immunobiology 2002; 205:467475.
  • 25
    Krarup A, Wallis R, Presanis JS et al. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE 2007; 2:e623.
  • 26
    Krarup A, Gulla KC, Gál P et al. The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen. Biochim Biophys Acta 2008; 1784:12941300.
  • 27
    Gulla KC, Gupta K, Krarup A et al. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology 2010; 129:482495.
  • 28
    Hess K, Ajjan R, Phoenix F et al. Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation. PLoS ONE 2012; 7:e35690.
  • 29
    La Bonte LR, Pavlov VI, Tan YS et al. Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis. J Immunol 2012; 188:885891.
  • 30
    Trendelenburg M, Theroux P, Stebbins A et al. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2010; 31:11811187.
  • 31
    Osthoff M, Katan M, Fluri F et al. Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients. PLoS ONE 2011; 6:e21338.
  • 32
    Mellbin LG, Bjerre M, Thiel S et al. Complement activation and prognosis in patients with type 2 diabetes and myocardical infarction. Diabetes Care 2012; 35:911917.
  • 33
    Zhang M, Hou YJ, Cavusoglu E et al. MASP-2 activation is involved in ischemia-related necrotic myocardial injury. Int J Cardiol 2011; http://dx.doi.org/10.1016/j.ijcard.2011.11.032
  • 34
    Cervera A, Planas AM, Justicia C et al. Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. PLoS ONE 2010; 5:e8433.
  • 35
    Schroeder V, Chatterjee T, Mehta H et al. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002; 88:10201025.
  • 36
    Schroeder V, Ortner E, Mono ML et al. Coagulation factor XIII activation peptide and subunit levels in patients with acute ischemic stroke: a pilot study. Thromb Res 2010; 126:e122127.
  • 37
    Brott T, Adams HP, Olinger CP et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20:864870.
  • 38
    Adams HP Jr, Bendixen BH, Kappelle LJ et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 1993; 24:3541.
  • 39
    Degn SE, Jensen L, Gál P et al. Biological variations of MASP-3 and MAp44, two splice products of the MASP1 gene involved in regulation of the complement system. J Immunol Methods 2010; 361:3750.
  • 40
    Thiel S, Jensen L, Degn SE et al. Mannan-binding lectin (MBL)-associated serine protease-1 (MASP-1), a serine protease associated with humoral pattern-recognition molecules: normal and acute-phase levels in serum and stoichiometry of lectin pathway components. Clin Exp Immunol 2012; 169:3848.
  • 41
    Schwaeble WJ, Lynch NJ, Clark JE et al. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA 2011; 108:75237528.
  • 42
    Orsini F, Villa P, Parrella S et al. Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation 2012; 126:14841494.
  • 43
    Møller-Kristensen M, Jensenius JC, Jensen L et al. Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals. J Immunol Methods 2003; 282:159167.
  • 44
    Ytting H, Christensen IJ, Thiel S et al. Biological variation in circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease-2 and the influence of age, gender and physical exercise. Scand J Immunol 2007; 66:458464.
  • 45
    Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly 2002; 132:241252.
  • 46
    Cortesio CL, Jian W. Mannan-binding lectin-associated serine protease 3 cleaves synthetic peptides and insulin-like growth factor-binding protein 5. Arch Biochem Biophys 2006; 449:164170.
  • 47
    Fischer F, Schulte H, Mohan S et al. Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease. Clin Endocrinol (Oxf) 2004; 61:595602.
  • 48
    Conti E, Musumeci MB, De Giusti M et al. IGF-1 and atherothrombosis: relevance to pathophysiology and therapy. Clin Sci 2011; 120:377402.